Background:Mantle cell lymphoma (MCL) is an incurable malignance, and MCL patients usually have high recurrence rate and poor prognosis. Additional therapeutic targets need to be discovered to improve the clinical outcome of MCL patients. This study aimed to explore the combined therapeutic effect of selinexor and decitabine in MCL.
Methods: MCL cells (Jeko, Mino, Rec1, and Z138) were treated with selinexor, decitabine, or in combination, and then cell proliferation, cell apoptosis, cell cycle were determined by CCK-8 and flow cytometry. RNA-seq was performed to elucidate the potential mechanism of the synergistic effect of selinexor and decitabine.
Results: Monotherapy with either selinexor or decitabine could inhibit cell proliferation, promote cell apoptosis, and induce cell cycle arrest in MCL cells. The combined treatment of selinexor and decitabine achieved greater inhibitory effect of cell proliferation and significantly increased cell apoptosis rate compared to their single treatment. RNA-seq confirmed that the synergistic effect of selinexor and decitabine could activate the MAPK signaling pathway.
Conclusions: The synergistic anti-tumor therapy of selinexor and decitabine is expected to be a powerful strategy for MCL treatment, which provides a new perspective for MCL patients.
No relevant conflicts of interest to declare.
This feature is available to Subscribers Only
Sign In or Create an Account Close Modal